Curated News
By: NewsRamp Editorial Staff
May 01, 2024
Immunic Inc CEO Shares Positive Trial Data in Peer-Reviewed Journal
TLDR
- Immunic Inc's Phase 2 trial data shows a significant reduction in lesions, indicating a potential advantage for MS treatment.
- The EMPhASIS trial data demonstrates a notable reduction in gadolinium-enhancing lesions and improvements in serum neurofilament light chain levels.
- The drug's potential to alter the management of all forms of MS and address disease progression independent of relapse activity could make a positive impact on patient care.
- The drug's unique profile combines safety and effectiveness, showing promise in altering the treatment landscape for multiple sclerosis.
Impact - Why it Matters
The publication of the trial data signifies a significant step forward in the understanding and potential treatment of multiple sclerosis. The notable reduction in lesions and the drug's unique profile could have a profound impact on addressing disease progression independent of relapse activity, offering hope to those suffering from MS. The ongoing progress in the field indicates potential advancements in the treatment landscape for MS.
Summary
Dr. Daniel Vitt of Immunic Inc (NASDAQ:IMUX) shared the extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) in the peer-reviewed journal, Neurology® Neuroimmunology & Neuroinflammation. The trial demonstrated a notable reduction in gadolinium-enhancing lesions by 78% and 74% in two high-dose groups compared with the placebo. This has the potential to alter the management of all forms of MS.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Immunic Inc CEO Shares Positive Trial Data in Peer-Reviewed Journal
